BG
MYGN icon

Bahl & Gaynor’s Myriad Genetics MYGN Stock Holding History

Bahl & Gaynor’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,511
Closed -$408K – 451
2015
Q1 		$408K Buy
11,511
+430
+4% +$15.4K 0.01% 331
2014
Q4 		$377K Buy
11,081
+240
+2% +$8.52K 0.01% 330
2014
Q3 		$418K Buy
10,841
+1,330
+14% +$49.6K 0.01% 308
2014
Q2 		$370K Buy
9,511
+150
+2% +$5.58K 0.01% 313
2014
Q1 		$320K Buy
+9,361
New +$290K 0.01% 329

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bahl & Gaynor's MYGN Position: Q2 2015 in Review

Bahl & Gaynor sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 11,511 shares — an estimated $408K sold.

Bahl & Gaynor first reported a position in MYGN in Q1 2014 and held it in 5 quarters. The position peaked at $418K in Q3 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

  • Bahl & Gaynor reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
  • Bahl & Gaynor sold 11,511 Myriad Genetics shares in Q2 2015, an estimated $408K.
  • Bahl & Gaynor first reported a position in Myriad Genetics in Q1 2014 and held it in 5 quarters.
  • Bahl & Gaynor's Myriad Genetics position peaked at $418K in Q3 2014.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Bahl & Gaynor's 13F filing for Q2 2015, filed 3 Aug 2015.